Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors

Buffier, P.; Bouillet, Benjamin; Smati, Sarra; Archambeaud, F.; Cariou, Bertrand; Vergès, Bruno

doi:10.1016/j.ando.2018.07.011

“…Importantly, some anticancer drugs can worsen dyslipidaemia. For example, the higher incidence of dyslipidaemia was found in the patients treated with nilotinib and other tyrosine kinase inhibitors [75].…”

Section: Hypercholesterolemia Cancer and Cardiovascular Diseasesmentioning

confidence: 99%

Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC)

Mercurio

¹

,

Cuomo

²

,

Dessalvi

³

et al. 2020

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is a well established risk factor for cardiovascular (CV) diseases. In addition, several studies indicate that MetS correlates with the increased risk of cancer in adults. The mechanisms linking MetS and cancer are not fully understood. Several risk factors involved in MetS are also cancer risk factors, such as the consumption of high calorie-food or high fat intake, low fibre intake, and sedentary lifestyle. Other common aspects of both cancer and MetS are oxidative stress and inflammation. In addition, some anticancer treatments can induce cardiotoxicity, including, for instance, left ventricular (LV) dysfunction and heart failure (HF), endothelial dysfunction and hypertension. In this review, we analyse several aspects of MetS, cancer and cardiotoxicity from anticancer drugs. In particular, we focus on oxidative stress in ageing, cancer and CV diseases, and we analyse the connections among CV risk factors, cancer and cardiotoxicity from anticancer drugs.

show abstract

“…21 Still, patients receiving nilotinib should have glucose levels and lipid profile monitored before, during, and after treatment. 22 For diabetic patients, self-monitoring and regular assessment of hemoglobin A1c are recommended. 22 Hyperlipidemia is another risk factor for AOEs, and our patient has an elevated cholesterol level.…”

Section: Glucose and Lipidsmentioning

confidence: 99%

“…22 For diabetic patients, self-monitoring and regular assessment of hemoglobin A1c are recommended. 22 Hyperlipidemia is another risk factor for AOEs, and our patient has an elevated cholesterol level. Imatinib may improve the lipid profile of patients, and nilotinib may worsen it, usually soon after treatment starts.…”

Section: Glucose and Lipidsmentioning

confidence: 99%

How to manage CML patients with comorbidities

Cortes

¹

2020

Blood

View full text Add to dashboard Cite

Patients with chronic myeloid leukemia (CML) often have comorbidities, at an incidence that might be higher than in the general population. Because of the favorable outcome of most patients with CML treated with tyrosine kinase inhibitors (TKIs), a greater number of comorbidities might be the most significant adverse feature for long-term survival. The presence of comorbidities may also affect the risk of developing adverse events with TKIs. This effect is perhaps best exemplified by the risk of developing arterio-occlusive events, which is greatest for patients who have other risk factors for such events, with the risk increasing with higher numbers of comorbidities. The coexistence of comorbidities in patients with CML not only may affect TKI selection but also demands close monitoring of the overall health condition of the patient to optimize safety and provide the opportunity for an optimal outcome to such patients. With optimal, holistic management of leukemia and all other conditions afflicting them, patients with CML and comorbidities may aim for a near-normal life expectancy, just as the more select patients enrolled in clinical trials now enjoy.

show abstract

“…34,35 Therefore, these patients can be treated with a TKI that is considered most Table 3. Suggested follow-up of patients with comorbidities for selected health conditions based on recommendations from an expert panel of cardiology 20 and endocrinology 22…”

Section: Renal Dysfunctionmentioning

confidence: 99%

How to manage CML patients with comorbidities

Cortés

¹

2020

View full text Add to dashboard Cite

Patients with chronic myeloid leukemia (CML) often have comorbidities, at an incidence that might be higher than in the general population. Because of the favorable outcome of most patients with CML treated with tyrosine kinase inhibitors (TKIs), a greater number of comorbidities might be the most significant adverse feature for long-term survival. The presence of comorbidities may also affect the risk of developing adverse events with TKIs. This effect is perhaps best exemplified by the risk of developing arterio-occlusive events, which is greatest for patients who have other risk factors for such events, with the risk increasing with higher numbers of comorbidities. The coexistence of comorbidities in patients with CML not only may affect TKI selection but also demands close monitoring of the overall health condition of the patient to optimize safety and provide the opportunity for an optimal outcome to such patients. With optimal, holistic management of leukemia and all other conditions afflicting them, patients with CML and comorbidities may aim for a near-normal life expectancy, just as the more select patients enrolled in clinical trials now enjoy.

show abstract

Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors

Cited by 23 publications

References 56 publications

Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC)

Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC)

How to manage CML patients with comorbidities

How to manage CML patients with comorbidities

Contact Info

Product

Resources

About